Shuangshuang Zhang

Shuangshuang Zhang

Auto-generated profile, based on publicly available information

Shuangshuang Zhang

Institute of Digestive Diseases, Xuzhou Medical University, Jiangsu, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
SZShuangshuang Zhang
Shuangshuang Zhang
LZLudan Zhao
Ludan Zhao
XPXu Peng
Xu Peng
Qiaomei SunQiaomei Sun
Qiaomei Sun
XLXiaoxiang Liao
Xiaoxiang Liao
HLHui Li
Hui Li

11 May 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JDJi Dai
Ji Dai
SZShuangshuang Zhang
Shuangshuang Zhang
HSHaohang Sun
Haohang Sun
YWYulian Wu
Yulian Wu
MYMeidi Yan
Meidi Yan

6 November 2015 in Planta Medica
Verified
Journal Article
Closed access
PDF file
YCYuepiao Cai
Yuepiao Cai
SZShuangshuang Zhang
Shuangshuang Zhang
QWQiqi Wang
Qiqi Wang
HSHao Sun
Hao Sun
MZMi Zhou
Mi Zhou
ZXZheng Xiang
Zheng Xiang
Nomilin is a potential anticancer agent. In this study, a rapid, sensitive, and simple ultra-performance liquid chromatography with tandem mass spectrometry methodology was established and validated to quantify nomilin in rat plasma. Plasma samples were prepared through liquid-liquid extraction using ethyl acetate. Chromatographic separation was performed using an Acquity HSS T3 column. Acetonitrile and water containing 0.1 % (v/v) formic acid were used as mobile phases at a flow rate of 0.3 mL/min. Nomilin and quercetin (internal standard) were detected and quantified via a triple quadrupole tandem mass spectrometer in the positive ion mode with multiple reaction monitoring. Tandem mass spectrometry detection was performed by monitoring the fragmentations of m/z 515.3 → m/z 161.0 and m/z 303.2 → m/z 153.1 of nomilin and quercetin, respectively. Good linearity (R2 > 0.996) was observed in the concentration range of 1 ng/mL to 500 ng/mL with a lower limit of quantification of 1 ng/mL for nomilin. The average extraction recoveries of nomilin and quercetin were > 82.3 % and 82.0 %, respectively. Intra- and interday precisions were less than 15 % and accuracy ranged from 85.0 % to 90.1 %. Indeed, the proposed method was successfully applied to analyze the pharmacokinetics of nomilin after 3 and 50 mg/kg nomilin were administered to rats via intravenous and oral routes, respectively.

10 September 2025 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
YLYiqun Li
Yiqun Li
ZWZhiyu Wang
Zhiyu Wang
SZShuangshuang Zhang
Shuangshuang Zhang
YHYanling Hua
Yanling Hua
XFXinting Fan
Xinting Fan
LLLi Li
Li Li
Background/Aims: The chronicity and recurrence of irritable bowel syndrome (IBS) pose significant burdens on patients’ lives, making it urgent to understand its underlying mechanisms. This study intends to investigate the function and regulatory mechanisms of miR 539-5p in IBS and lay the foundation for the creation of more effective therapeutic strategies. Materials and Methods: Rat model of IBS with diarrhea (IBS-D) was established and evaluated by the abdominal withdrawal reflex. The IBS cellular model was established in vitro using lipopolysaccharide (LPS), and real-time quantitative polymerase chain reaction was used to assess the changes in the miR-539-5p expression. Cell counting kit-8 assays, flow cytometry, and enzyme-linked immu nosorbent assay were used to evaluate the effects of different treatments on cell viability, paracellular permeability, apoptosis, and inflammatory responses. Bioinformatics techniques and dual-luciferase reporter gene assays were leveraged to forecast and confirm the interaction between miR-539-5p and the KDM6A gene. Results: In IBS-D rats, miR-539-5p was conspicuously downregulated, and miR-539-5p overexpression could improve the symptoms of rats. Under exposure to LPS, the expression of miR-539-5p was evidently decreased. Upregulating miR-539-5p could significantly mitigate LPS-induced cellular damage, namely inhibiting the apoptosis of intestinal mucosal epithelial cells, promoting cell prolifera tion, reducing paracellular permeability, and suppressing the inflammatory response. KDM6A, as the target gene of miR-539-5p, was remarkably upregulated in IBS-D rats and cells exposed to LPS. KDM6A overexpression counteracts the protective effects mediated by the upregulation of miR-539 5p. Conclusion: miR-539-5p may be involved in regulating the pathological processes of IBS-D by targeting KDM6A. Cite this article as: Li Y, Wang Z, Zhang S, Hua Y, Fan X, Li L. MiR-539-5p regulates irritable bowel syndrome pathological processes by targeting KDM6A. Turk J Gastroenterol. Published online September 10, 2025. doi: 10.5152/tjg.2025.24684.